In this era of continued emergence of zoonotic virus infections, the rapid development of
rodent models represents a critical barrier to public health preparedness, including the …

The identification of patient-specific tumor antigens is complicated by the low frequency of T
cells specific for each tumor antigen. Here we describe NeoScreen, a method that enables …

Cancer somatic mutations can generate neoantigens that distinguish malignant from normal
cells,,,,,,. However, the personalized identification and validation of neoantigens remains a …

Adoptive cell therapy (ACT) is a kind of immunotherapy in which T cells are genetically
modified to express a chimeric antigen receptor (CAR) or T cell receptor (TCR), and ACT …

Background Knowledge about and identification of T cell tumor antigens may inform the
development of T cell receptor-engineered adoptive cell transfer or personalized cancer …

Recent breakthroughs in cancer immunotherapy and decreasing costs of high-throughput
technologies have sparked intensive research into tumour–immune cell interactions using …

Background MHC class II binding predictions are widely used to identify epitope candidates
in infectious agents, allergens, cancer and autoantigens. The vast majority of prediction …

Recent advances in immune checkpoint blockade therapy have revolutionized the treatment
of cancer. Tumor-specific antigens that are generated by somatic mutation, neoantigens, can …

Vaccination is generally considered to be the most effective method of preventing infectious
diseases. All vaccinations work by presenting a foreign antigen to the immune system in …

Impressive results have been achieved by adoptively transferring T-cells expressing CD19-
specific CARs with binding domains from murine mAbs to treat B-cell malignancies. T-cell …